Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Yanae, Masashi ^a   Tsubaki, Masanobu ^a   Satou, Takao ^b   Itoh, Tatsuki ^b   Imano, Motohiro ^b   Yamazoe, Yuzuru ^c   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KINDAI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Akt; C6 glioma; ERK; statins

Indexed keywords

CASPASE 3; COMPACTIN; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; SIMVASTATIN; 3 HYDROXY 3 METHYLGLUTARYL COENZYME A; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A; ACYL COENZYME A; ISOPRENOID PHOSPHATE; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 3;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; ENZYME ACTIVITY; GLIOBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL GROWTH; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; HUMAN; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ACYL COENZYME A; APOPTOSIS; CELL GROWTH PROCESSES; CELL SURVIVAL; ENZYME ACTIVATION; FEMALE; GLIOBLASTOMA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEVALONIC ACID; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; POLYISOPRENYL PHOSPHATES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 81155157844     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-74     Document Type: Article

References (19)

1. Brain tumors. DeAngelis LM, N Engl J Med 2001 344 114 123 10.1056/NEJM200101113440207 11150363 (Pubitemid 32052502)
2. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Reardon DA, Wen PY, Oncologist 2006 11 152 164 10.1634/theoncologist.11-2-152 16476836 (Pubitemid 43261762)
3. Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK. Nishida S, Matsuoka H, Tsubaki M, Tanimori Y, Yanae M, Fujii Y, Iwaki M, Mol Cell Biochem 2005 269 109 114 10.1007/s11010-005-3086-0 15786722 (Pubitemid 40287807)
4. Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF- as angiogenic factors in mouse osteosarcoma. Tsubaki M, Yamazoe Y, Yanae M, Satou T, Itoh T, Kaneko J, Kidera Y, Moriyama K, Nishida S, Cytokine 2011 54 100 107 10.1016/j.cyto.2011.01.005 21292498
5. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ, Cancer Res 2004 64 6461 6468 10.1158/0008-5472.CAN-04-0866 15374955 (Pubitemid 39297901)
6. Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells. Jiang Z, Zheng X, Lytle RA, Higashikubo R, Rich KM, J Neurochem 2004 89 168 178 10.1111/j.1471-4159.2004.02319.x 15030401 (Pubitemid 38420686)
7. Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Koyuturk M, Ersoz M, Altiok N, Neurosci Lett 2004 370 212 217 10.1016/j.neulet.2004.08.020 15488325 (Pubitemid 39370881)
8. Fluvastatin induces apoptosis on human tongue carcinoma cell line HSC-3. Fujiwara K, Tsubaki M, Yamazoe Y, Nishiura S, Kawaguchi T, Ogaki M, Nishinobo M, Shimamoto K, Moriyama K, Nishida S, Yakugaku Zasshi 2008 128 153 158 10.1248/yakushi.128.153 18176067
9. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC, Anticancer Res 2000 20 2761 2771 10953355 (Pubitemid 30614496)
10. Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts. Cerezo-Guisado MI, García- Román N, García-Marín LJ, Alvarez-Barrientos A, Bragado MJ, Lorenzo MJ, Biochem J 2007 401 175 183 10.1042/BJ20060731 16952276 (Pubitemid 46114611)
11. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Taylor-Harding B, Orsulic S, Karlan BY, Li AJ, Gynecol Oncol 2010 119 549 556 10.1016/j.ygyno.2010.08.017 20837358
12. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Lee MV, Fong EM, Singer FR, Guenette RS, Cancer Res 2001 61 2602 2608 11289137 (Pubitemid 32685845)
13. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI, Br J Haematol 1997 98 665 672 10.1046/j.1365-2141.1997.2713086.x 9332325 (Pubitemid 27386550)
14. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW, Br J Haematol 2005 130 912 925 10.1111/j.1365-2141.2005.05696.x 16156861 (Pubitemid 43899732)
15. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells. Tsubaki M, Kato C, Nishinobo M, Ogaki M, Satou T, Ito T, Kusunoki T, Fujiwara K, Yamazoe Y, Nishida S, Cancer Sci 2008 99 152 158 17979996 (Pubitemid 350239044)
16. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Park IH, Kim JY, Jung JI, Han JY, Invest New Drugs 2010 28 791 799 10.1007/s10637-009-9319-4 19760159
17. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Asano T, Hayakawa M, Clin Cancer Res 2004 10 8648 8655 10.1158/1078-0432.CCR-04-1568 15623649 (Pubitemid 40053433)
18. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Sondergaard TE, Pedersen PT, Andersen TL, Søe K, Lund T, Ostergaard B, Garnero P, Delaisse JM, Plesner T, Hematol Oncol 2009 27 17 22 10.1002/hon.869 18668701
19. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Skottheim IB, Gedde-Dahl A, Hejazifar S, Hoel K, Asberg A, Eur J Pharm Sci 2008 33 317 325 10.1016/j.ejps.2007.12.009 18294823